Leerink notes uniQure (QURE) reported topline results from the pivotal Phase 1/2 study of AMT-130 in Huntington’s disease, meeting their primary endpoint with statistical significance slowing of disease progression as measured by the composite United Huntington’s Disease Rating Scale at 3 years that did not meaningfully erode vs. 2 years plus several key secondaries, which the firm thinks limits the regulatory risk for this program going forward. Leerink thinks the data can support an approval with minimal need for regulatory flexibility from the FDA, which has been a concern for investors, and the firm would not be surprised to see the stock trade up 100% or more on today’s news. Leerink has an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- PTC shares to see pressure on ‘compelling’ uniQure data, says Citi
- PTC Therapeutics down 3% after uniQure Huntington’s disease data
- Morning Movers: uniQure skyrockets after AMT-130 trial meets primary endpoint
- uniQure soars 167% to $36.50 in pre-market after AMT-130 study met endpoint
- uniQure announces Phase I/II study of AMT-130 met primary endpoint